These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 4097002)

  • 1. Thyroid suppressibility and long-acting thyroid stimulator in thyrotoxicosis.
    Silverstein GE; Burke G
    Arch Intern Med; 1970 Oct; 126(4):615-20. PubMed ID: 4097002
    [No Abstract]   [Full Text] [Related]  

  • 2. Suppressibility of thyroid function despite high levels of long-acting thyroid stimulator.
    Wong ET; Doe RP
    Ann Intern Med; 1972 Jan; 76(1):77-84. PubMed ID: 4112158
    [No Abstract]   [Full Text] [Related]  

  • 3. [Significance of long-acting thyroid stimulator. Reflections on the 1st series of results].
    Tourneur R; Letonturier P; Sénécal P
    Minerva Med; 1974 Mar; 65(19):995-8. PubMed ID: 4406464
    [No Abstract]   [Full Text] [Related]  

  • 4. [Thyroid function and the state of the hypothalamus-hypophysis-thyroid in patients with diffuse toxic goiter after treatment].
    Aliakparova ASh
    Sov Med; 1973 Dec; 36(12):45-8. PubMed ID: 4130665
    [No Abstract]   [Full Text] [Related]  

  • 5. Dissociation of serum LATS content and thyroid suppressibility during treatment of hyperthyroidism.
    Chopra IJ; Solomon DH; Johnson DE; Chopra U; Fischer DA
    J Clin Endocrinol Metab; 1970 Apr; 30(4):524-8. PubMed ID: 5435290
    [No Abstract]   [Full Text] [Related]  

  • 6. Suppressibility of thyroid function during treatment with antithyroid drugs in Grave's disease.
    Wils JA; Kloppenborg PW
    J Clin Endocrinol Metab; 1970 Mar; 30(3):406-7. PubMed ID: 4189571
    [No Abstract]   [Full Text] [Related]  

  • 7. Thyroid physiology and functional tests.
    Zellmann HE
    Major Probl Clin Surg; 1980; 15():70-84. PubMed ID: 6893732
    [No Abstract]   [Full Text] [Related]  

  • 8. Abnormalities of hypothalamo-hypophyseal-thyroid axis in patients with Graves' ophthalmopathy.
    Chopra IJ; Chopra U; Orgiazzi J
    J Clin Endocrinol Metab; 1973 Dec; 37(6):955-67. PubMed ID: 4201831
    [No Abstract]   [Full Text] [Related]  

  • 9. Investigation of endocrine exophthalmos.
    Bowden AN; Ross FC
    Proc R Soc Med; 1969 Jan; 62(1):13-5. PubMed ID: 5818230
    [No Abstract]   [Full Text] [Related]  

  • 10. [L.A.T.S. activity during hyperthyroidism. Apropos of 143 cases of Basedow's disease].
    Letonturier P; Tourneur R; Sénécal P
    Ann Med Interne (Paris); 1974 May; 125(5):463-7. PubMed ID: 4140703
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of triiodothyronine on cervical lymphoid structures, thyroid activity, IgG and IgM immunoglobulin level and exophthalmos in Graves' disease.
    Mahaux JE; Chamla-Soumenkoff J; Delcourt R; Nagel N; Levin S
    Acta Endocrinol (Copenh); 1969 Jul; 61(3):400-6. PubMed ID: 4184992
    [No Abstract]   [Full Text] [Related]  

  • 12. Thyroid physiology and functional tests.
    Zellmann HE
    Major Probl Clin Surg; 1974; 15(0):55-70. PubMed ID: 4138680
    [No Abstract]   [Full Text] [Related]  

  • 13. Thyroid gland in Graves' disease: victim or culprit?
    Chopra IJ; Solomon DH; Johnson DE; Chopra U
    Metabolism; 1970 Oct; 19(10):760-72. PubMed ID: 5535910
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of thyroidal suppression by triiodothyronine during six months' treatment of thyrotoxicosis with antithyroid drugs.
    Alexander WD; Harden RM; Shimmins J; McLarty D; McGill P
    J Clin Endocrinol Metab; 1967 Dec; 27(12):1682-9. PubMed ID: 4168655
    [No Abstract]   [Full Text] [Related]  

  • 15. Large doses of radioiodide in Graves' disease: effect on ophthalmopathy and long-acting thyroid stimulator.
    Pequegnat EP; Mayberry WE; McConahey WM; Wyse EP
    Mayo Clin Proc; 1967 Dec; 42(12):802-11. PubMed ID: 4169552
    [No Abstract]   [Full Text] [Related]  

  • 16. Does LATS cause hyperthyroidism in Graves' disease? (A review biased toward the affirmative).
    McKenzie JM
    Metabolism; 1972 Sep; 21(9):883-94. PubMed ID: 4115791
    [No Abstract]   [Full Text] [Related]  

  • 17. [Simultaneous determination of thyreotropic hormone and long-acting thyroid stimulator in the plasma of Basedow patients].
    Földes J; Gesztesi E; Takács I
    Orv Hetil; 1970 Dec; 111(52):3067-70. PubMed ID: 4099957
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of radioablation of the thyroid gland in Graves' disease with high levels of long-acting thyroid stimulator (LATS).
    Volpé R; Desbarats-Schonbaum ML; Schonbaum E; Row VV; Ezrin C
    Am J Med; 1969 Feb; 46(2):217-26. PubMed ID: 5818477
    [No Abstract]   [Full Text] [Related]  

  • 19. LATS protector and abnormal thyroid stimulation in diffuse toxic goitre.
    Stewart RD
    N Z Med J; 1975 Jan; 81(531):24. PubMed ID: 1055311
    [No Abstract]   [Full Text] [Related]  

  • 20. The long-acting thyroid stimulatory: is it of importance in Graves' disease.
    McKenzie JM; Zakarija M; D'Amour P; Joasoo A
    N Z Med J; 1975 Jan; 81(531):18-21. PubMed ID: 165442
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.